Shares of Innoviva, Inc. (NASDAQ:INVA) have been given a consensus rating of “Hold” by the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.33.

A number of equities research analysts recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Innoviva from $7.00 to $8.00 and gave the company an “underweight” rating in a research report on Friday. ValuEngine raised shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Monday. Stifel Nicolaus reissued a “hold” rating and issued a $15.00 price target on shares of Innoviva in a research report on Friday, July 28th. Zacks Investment Research raised shares of Innoviva from a “hold” rating to a “strong-buy” rating and set a $16.00 price target for the company in a research report on Monday, July 31st. Finally, Cowen and Company set a $16.00 price target on shares of Innoviva and gave the company a “buy” rating in a research report on Friday, July 28th.

Innoviva (NASDAQ INVA) traded down 2.58% during trading on Friday, hitting $14.37. The company had a trading volume of 168,896 shares. Innoviva has a 52-week low of $8.67 and a 52-week high of $14.87. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of 18.08 and a beta of 2.60. The firm’s 50 day moving average is $13.64 and its 200-day moving average is $12.95.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The firm had revenue of $58.60 million during the quarter, compared to analysts’ expectations of $50.53 million. During the same period in the previous year, the company earned $0.13 earnings per share. Innoviva’s quarterly revenue was up 80.3% compared to the same quarter last year. On average, equities analysts forecast that Innoviva will post $1.16 earnings per share for the current year.

Several large investors have recently made changes to their positions in INVA. Russell Investments Group Ltd. purchased a new stake in shares of Innoviva in the first quarter valued at about $688,000. Great West Life Assurance Co. Can raised its holdings in shares of Innoviva by 7.5% in the first quarter. Great West Life Assurance Co. Can now owns 107,310 shares of the biotechnology company’s stock valued at $1,482,000 after buying an additional 7,475 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Innoviva by 11.6% in the first quarter. BNP Paribas Arbitrage SA now owns 15,984 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 1,656 shares during the last quarter. Comerica Bank raised its holdings in shares of Innoviva by 4.5% in the first quarter. Comerica Bank now owns 85,950 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 3,673 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Innoviva by 47.8% in the first quarter. UBS Asset Management Americas Inc. now owns 39,134 shares of the biotechnology company’s stock valued at $541,000 after buying an additional 12,650 shares during the last quarter. 69.06% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Innoviva, Inc. (INVA) Receives Average Rating of “Hold” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/innoviva-inc-inva-receives-average-rating-of-hold-from-analysts.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.